A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

Recruiting

Phase 3

PalopegteriparatideA Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

Sponsor:

Ascendis Pharma Bone Diseases A/S

Code:

NCT07081997

Conditions

Hypoparathyroidism

Endocrine System Diseases

Parathyroid Diseases

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Palopegteriparatide Experimental Arm

Palopegteriparatide Control Arm

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-26. This information was provided to ClinicalTrials.gov by Ascendis Pharma Bone Diseases A/S on 2026-05-04.